1
|
Martínez-Gómez LE, Herrera-López B, Martinez-Armenta C, Ortega-Peña S, Camacho-Rea MDC, Suarez-Ahedo C, Vázquez-Cárdenas P, Vargas-Alarcón G, Rojas-Velasco G, Fragoso JM, Vidal-Vázquez P, Ramírez-Hinojosa JP, Rodríguez-Sánchez Y, Barrón-Díaz D, Moreno ML, Martínez-Ruiz FDJ, Zayago-Angeles DM, Mata-Miranda MM, Vázquez-Zapién GJ, Martínez-Cuazitl A, Barajas-Galicia E, Bustamante-Silva L, Zazueta-Arroyo D, Rodríguez-Pérez JM, Hernández-González O, Coronado-Zarco R, Lucas-Tenorio V, Franco-Cendejas R, López-Jácome LE, Vázquez-Juárez RC, Magaña JJ, Cruz-Ramos M, Granados J, Hernández-Doño S, Delgado-Saldivar D, Ramos-Tavera L, Coronado-Zarco I, Guajardo-Salinas G, Muñoz-Valle JF, Pineda C, Martínez-Nava GA, López-Reyes A. ACE and ACE2 Gene Variants Are Associated With Severe Outcomes of COVID-19 in Men. Front Immunol 2022; 13:812940. [PMID: 35250987 PMCID: PMC8892378 DOI: 10.3389/fimmu.2022.812940] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 01/25/2022] [Indexed: 01/08/2023] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic, affecting more than 219 countries and causing the death of more than 5 million people worldwide. The genetic background represents a factor that predisposes the way the host responds to SARS-CoV-2 infection. In this sense, genetic variants of ACE and ACE2 could explain the observed interindividual variability to COVID-19 outcomes. In order to improve the understanding of how genetic variants of ACE and ACE2 are involved in the severity of COVID-19, we included a total of 481 individuals who showed clinical manifestations of COVID-19 and were diagnosed by reverse transcription PCR (RT-PCR). Genomic DNA was extracted from peripheral blood and saliva samples. ACE insertion/deletion polymorphism was evaluated by the high-resolution melting method; ACE single-nucleotide polymorphism (SNP) (rs4344) and ACE2 SNPs (rs2285666 and rs2074192) were genotyped using TaqMan probes. We assessed the association of ACE and ACE2 polymorphisms with disease severity using logistic regression analysis adjusted by age, sex, hypertension, type 2 diabetes, and obesity. The severity of the illness in our study population was divided as 31% mild, 26% severe, and 43% critical illness; additionally, 18% of individuals died, of whom 54% were male. Our results showed in the codominant model a contribution of ACE2 gene rs2285666 T/T genotype to critical outcome [odds ratio (OR) = 1.83; 95%CI = 1.01–3.29; p = 0.04] and to require oxygen supplementation (OR = 1.76; 95%CI = 1.01–3.04; p = 0.04), in addition to a strong association of the T allele of this variant to develop critical illness in male individuals (OR = 1.81; 95%CI = 1.10–2.98; p = 0.02). We suggest that the T allele of rs2285666 represents a risk factor for severe and critical outcomes of COVID-19, especially for men, regardless of age, hypertension, obesity, and type 2 diabetes.
Collapse
Affiliation(s)
- Laura E. Martínez-Gómez
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Brígida Herrera-López
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Carlos Martinez-Armenta
- Postgrado en Biología Experimental, Dirección de Ciencias Biológicas y de la Salud (DCBS), Universidad Autónoma Metropolitana Iztapalapa, Mexico City, Mexico
| | - Silvestre Ortega-Peña
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - María del Carmen Camacho-Rea
- Departamento de Nutrición Animal, Departamento de Inmunogenética, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaría de Salud, Mexico City, Mexico
| | - Carlos Suarez-Ahedo
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Paola Vázquez-Cárdenas
- Centro de Innovación Médica Aplicada, Subdirección de Epidemiología e Infectología, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
| | - Gilberto Vargas-Alarcón
- Departamento de Biología Molecular y Unidad de Cuidados Intensivos, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico
| | - Gustavo Rojas-Velasco
- Departamento de Biología Molecular y Unidad de Cuidados Intensivos, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico
| | - José Manuel Fragoso
- Departamento de Biología Molecular y Unidad de Cuidados Intensivos, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico
| | - Patricia Vidal-Vázquez
- Centro de Innovación Médica Aplicada, Subdirección de Epidemiología e Infectología, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
| | - Juan P. Ramírez-Hinojosa
- Centro de Innovación Médica Aplicada, Subdirección de Epidemiología e Infectología, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
| | - Yunuen Rodríguez-Sánchez
- Centro de Innovación Médica Aplicada, Subdirección de Epidemiología e Infectología, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
| | - David Barrón-Díaz
- Centro de Innovación Médica Aplicada, Subdirección de Epidemiología e Infectología, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
| | - Mariana L. Moreno
- Nuevo Hospital General Delegación Regional Sur de la Ciudad de México ISSSTE, Mexico City, Mexico
| | | | - Dulce M. Zayago-Angeles
- Nuevo Hospital General Delegación Regional Sur de la Ciudad de México ISSSTE, Mexico City, Mexico
| | - Mónica Maribel Mata-Miranda
- Laboratorio de Biología Celular y Tisular, Laboratorio de Embriología, Escuela Militar de Medicina, Universidad del Ejército y Fuerza Aérea, Ciudad de México, Mexico
| | - Gustavo Jesús Vázquez-Zapién
- Laboratorio de Biología Celular y Tisular, Laboratorio de Embriología, Escuela Militar de Medicina, Universidad del Ejército y Fuerza Aérea, Ciudad de México, Mexico
| | - Adriana Martínez-Cuazitl
- Laboratorio de Biología Celular y Tisular, Laboratorio de Embriología, Escuela Militar de Medicina, Universidad del Ejército y Fuerza Aérea, Ciudad de México, Mexico
| | - Edith Barajas-Galicia
- Servicio de Cirugía General, Hospital Central Norte Petróleos Mexicanos (PEMEX), Mexico City, Mexico
| | - Ludwing Bustamante-Silva
- Servicio de Cirugía General, Hospital Central Norte Petróleos Mexicanos (PEMEX), Mexico City, Mexico
| | - Diana Zazueta-Arroyo
- Servicio de Cirugía General, Hospital Central Norte Petróleos Mexicanos (PEMEX), Mexico City, Mexico
| | - José Manuel Rodríguez-Pérez
- Departamento de Biología Molecular y Unidad de Cuidados Intensivos, Instituto Nacional de Cardiología Ignacio Chavez, Mexico City, Mexico
| | - Olivia Hernández-González
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Roberto Coronado-Zarco
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Vania Lucas-Tenorio
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Rafael Franco-Cendejas
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Luis Esau López-Jácome
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Rocío Carmen Vázquez-Juárez
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Jonathan J. Magaña
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Marlid Cruz-Ramos
- Programa de Investigadoras e investigadores por México del Consejo Nacional de Ciencia y Tecnología (CONACYT), Instituto Nacional de Cancerología, Mexico City, Mexico
| | - Julio Granados
- Departamento de Nutrición Animal, Departamento de Inmunogenética, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaría de Salud, Mexico City, Mexico
| | - Susana Hernández-Doño
- Departamento de Nutrición Animal, Departamento de Inmunogenética, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaría de Salud, Mexico City, Mexico
| | - Diego Delgado-Saldivar
- Departamento de Nutrición Animal, Departamento de Inmunogenética, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaría de Salud, Mexico City, Mexico
| | - Luis Ramos-Tavera
- Departamento de Nutrición Animal, Departamento de Inmunogenética, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Secretaría de Salud, Mexico City, Mexico
| | - Irma Coronado-Zarco
- Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Mexico City, Mexico
| | | | - José Francisco Muñoz-Valle
- Instituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico
| | - Carlos Pineda
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
| | - Gabriela Angélica Martínez-Nava
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
- *Correspondence: Alberto López-Reyes, ; Gabriela Angélica Martínez-Nava,
| | - Alberto López-Reyes
- Laboratorio de Gerociencias, Dirección General, Medicina de Rehabilitación, Laboratorio de Infectología, Departamento de Reconstrucción Articular, Laboratorio de Medicina Genómica, Laboratorio Facilitador, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Secretaría de Salud, Mexico City, Mexico
- *Correspondence: Alberto López-Reyes, ; Gabriela Angélica Martínez-Nava,
| |
Collapse
|
2
|
Holguín-Peña RJ, Vázquez-Juárez RC, Martínez-Soriano JP. First Report of a 16SrI-B Group Phytoplasma Associated with a Yellows-Type Disease Affecting Tomato Plants in the Baja California Peninsula of Mexico. Plant Dis 2007; 91:328. [PMID: 30780586 DOI: 10.1094/pdis-91-3-0328b] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Since 2000, a phytoplasma-like disease (locally known as "permanent yellowing") was observed on tomatoes (Lycopersicon esculentum Mill.) grown in the Valle de San Quintín in northern Baja California Peninsula. Affected plants showed general chlorosis, severe stunting, upwardly rolled leaves, bronzing of mature leaves, purple discoloration of veins, "little leaf", abnormal floral structures, and excessive branching of axillary shoots. Total DNA extracted from symptomatic and asymptomatic plants was used in nested (n)-PCR assays driven by phytoplasma-universal primer pair P1/P7 (3), followed by primer pair R16F2n/R16R2 (1) targeting the 16S ribosomal RNA gene of the putative phytoplasma. PCR conditions (direct and nested) were conducted as previously described (l,3). Restriction fragment length polymorphism (RFLP) patterns of nPCR-amplified products (≈ 1.25-kbp 16S rDNA fragments) digested with enzymes AluI, MseI, HhaI, and HpaII showed that 85% (17 of 20) of PCR-positive tomato samples had restriction patterns typical of phytoplasmas belonging to the aster yellows group, subgroup B (16SrI-B) "Candidatus Phytoplasma asteris" (2). Only 10% (2 of 20) of the samples were associated with a phytoplasma related to the 16SrXIII-A Mexican periwinkle virescence group (formerly group 16SrI, subgroup I). None of the symptomless plants tested positive. Subsequently, these results were confirmed by nPCR using 16SrI specific primer pair P1/Aint (4) and specific primers rp(I-B)F1/rp(I-B)R1 that amplify the ribosomal protein (rp) gene operon of aster yellows phytoplasma subgroup B (16SrI-B[rp-B]) (1). The presence of the phytoplasmas in symptomatic plants was confirmed by scanning electron microscopy. Characteristic yellow symptoms could be experimentally reproduced by graft inoculation of tomato seedlings (cv. Maya) with tissue of field-infected plants. Symptoms similar to those of field-grown diseased plants were observed consistently in most of the plants, and when graft transmitted from tomato to periwinkle (Catharantus roseus (L.) G. Don), symptoms of virescencent, small flowers were observed. In contrast, no symptoms were observed on plants grafted with tissues from healthy plants. In Baja California, it appears that at least two distinct phytoplasmas are involved in the disease complex. To our knowledge, this is the first molecular evidence of the presence of a phytoplasma associated with yellows-type diseases in the major tomato cultivation areas of the peninsula. References: (1) I.-M. Lee et al. Phytopathology 93:1368, 2003. (2) I.-M. Lee et al. Int. J. Syst. Evol. Microbiol. 54:1037, 2004. (3) B. Schneider et al. Page 369 in: Molecular and Diagnostic Procedures in Mycoplasmology. Academic Press, San Diego, CA, 1995. (4) C. D. Smart et al. Appl. Environ. Microbiol. 62:2988, 1996.
Collapse
Affiliation(s)
- R J Holguín-Peña
- Laboratorio de Biología Molecular de Plantas, Centro de Investigaciones Biológicas del Noroeste, La Paz, B.C.S. 23000, Mexico
| | - R C Vázquez-Juárez
- Laboratorio de Biología Molecular de Plantas, Centro de Investigaciones Biológicas del Noroeste, La Paz, B.C.S. 23000, Mexico
| | - J P Martínez-Soriano
- Centro de Investigación y de Estudios Avanzados Campus Guanajuato, Irapuato, Gto. 36500, Mexico
| |
Collapse
|
3
|
Holguín-Peña RJ, Vázquez-Juárez RC, Rueda-Puente EO. Bacterial Canker Caused by Clavibacter michiganensis subsp. michiganensis on Tomato in the Baja California Peninsula of Mexico. Plant Dis 2006; 90:1550. [PMID: 30780975 DOI: 10.1094/pd-90-1550a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
During the 2005 tomato-growing (Lycopersicon esculentum Mill.) season, an apparent bacterial disease with cankers on the stems and bird's eye lesions on the fruit appeared in commercial fields and greenhouses in the San Quintin and San Simon areas (a 60-mile long coastal plain) near the central region of the Baja California Peninsula of Mexico. The disease was found in midseason, especially when plants were flowering, and the mature and ripe stage. Incidence ranged from 4 to 46%, which represented an important loss in field and greenhouse production. Symptomatic plants showed reddish brown cavities in the stem, discoloration, and water soaking of vascular tissue. Diseased tissues were washed with phosphate buffer and placed on semiselective Clavibacter medium (SCM) (1), and a gram-positive, nonmotile, nonspore-forming, aerobic, curved rod bacterium was consistently isolated and morphologically characterized. Twenty-eight isolates were identified as Clavibacter michiganensis subsp. michiganensis by polymerase chain reaction (PCR) technology with primers CMM5/CMM6 to amplify a fragment of approximately 6.2 kb (2). The isolates were also identified by REP-PCR (repetitive extragenic palindromic PCR) genomic fingerprinting techniques (3) with REP and BOX primer sets (4). Pathogenicity tests consisting of three replicates of 4-week-old tomato seedlings (cv. Tequila) were performed by spraying (twice, 2 days apart) inocula at 108 CFU/ml. Control seedlings were sprayed with sterile water. Inoculated plants previously covered in polyethylene bags were incubated in a growth chamber at 25°C for 48 h. Within 3 weeks, symptoms of reddish-brown cavities, water-soaked lesions, and asymmetrical wilting appeared on inoculated plants and were similar to those symptoms observed in the field. No symptoms were observed on control plants. Confirmation of the causal agent was done by culturing the bacteria on SCM and PCR analysis. Occurrence of the disease in San Quintin Valley is relevant because the disease is one of the five most serious tomato diseases in the peninsula. Moreover, the potential spread of the pathogen by tomato seedlings represents a permanent risk to other pathogen-free areas in the peninsula. Although bacterial canker has been observed in Baja California (Punta Colonet, Vicente Guerrero, San Quintin, and San Simon), to our knowledge, this is the first confirmation of C. michiganensis subsp. michiganensis in Baja, Mexico. References: (1). C. Alarcon et al. Phytopathology 88:306, 1998. (2) J. Dreier et al. Phytopathology 85:462, 1995. (3) F. J. Louws et al. Phytopathology 88:862, 1998. (4) J. Versalovic et al. Methods Mol. Cell. Biol. 5:25, 1994.
Collapse
Affiliation(s)
- R J Holguín-Peña
- Laboratorio de Biología Molecular de Plantas, Centro de Investigaciones Biológicas del Noroeste, La Paz, B.C.S. 23000, Mexico
| | - R C Vázquez-Juárez
- Laboratorio de Biología Molecular de Plantas, Centro de Investigaciones Biológicas del Noroeste, La Paz, B.C.S. 23000, Mexico
| | | |
Collapse
|